LivaNova PLC LIVN
LivaNova PLC is a market-leading global medical technology company. 10-K, Item 1
- Employees
- 3,300
- Headquarters
- Gloucester
- Next results
- around Feb 24, 2027
Where each dollar of revenue went, FY2024
Revenue of $1.3B through the costs to a net profit of $63.2M · income statement of the 10-K
LIVN among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
14 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 25, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Going concern language“In addition, future unanticipated large liability claims may raise substantial doubt about LivaNova’s ability to continue as a going concern.”
-
Receivables +11.8% ($193.2M to $216.0M) vs revenue +10.7% ($1.3B to $1.4B), +1.1 pts apart
9 more checks with nothing to note
-
Cash from operations $254.3M vs net income −$242.5M (FY ending Dec 31, 2025)
-
Inventory +11.6% ($147.6M to $164.7M) vs revenue +10.7% ($1.3B to $1.4B), +0.9 pts apart
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Goodwill Impairment Assessment - Cardiopulmonary Reporting Unit
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
14 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Changes in global trade policies, including the imposition of tariffs, trade restrictions, export controls, sanctions, or other protectionist or retaliatory measures by the U.S. or other jurisdictions, may adversely affect LivaNova’s business, financial condition, and results of operations. Global trade conditions have become…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Failure to protect, maintain, or upgrade LivaNova’s IT systems or products, or safeguard against cybersecurity incidents, service disruptions, or data corruption could have a material adverse effect on LivaNova’s business, results of operations, financial condition and reputation.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
LivaNova operates in a highly competitive market characterized by increasingly complex products that are expensive and time-consuming to develop and manufacture. The Company’s success depends on several factors, including its ability to appropriately allocate the Company’s R&D resources, integrate advanced software and AI capabilities,…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
AI technologies are increasingly being used across the global business landscape, including in the development of new or improved products and therapies in the medical technology industry. LivaNova has already employed certain AI technologies in its business in an attempt to enhance the Company’s products, technology, and therapies and…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $1.0B | $1.2B | $1.3B | $1.4B |
| Net income | −$86.2M | $17.5M | $63.2M | −$242.5M |
| Operating cash flow | $69.9M | $74.9M | $183.0M | $254.3M |
| Free cash flow | $43.4M | $39.9M | $135.9M | $173.3M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$1.4B ▲ 10.7% in FY2025−$242.5M in FY2025$173.3M ▲ 27.5% in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026Shvartsburg Alex (Officer) gave notice of a planned sale of 2,500 shares worth about $227K Form 144, approximate sale date Nov 12, 2026, under a 10b5-1 plan adopted Aug 10, 2026
-
Planned saleNov 4, 2026Alex Shvartsburg (Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 10,000 shares, runs to Aug 11, 2027
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
LivaNova PLC, Gloucester · from the 10-K filed Feb 25, 2026
LivaNova PLC is a market-leading global medical technology company. The Company designs, develops, manufactures, markets, and sells products, therapies, and services that are consistent with LivaNova’s mission to “create ingenious medical solutions that ignite patient turnarounds.” LivaNova is a public limited company organized under the laws of England and Wales and is headquartered in London, England. LivaNova’s ordinary shares are listed for trading on the Nasdaq under the symbol “LIVN.”
- Headquarters
- Gloucester
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- United Kingdom
Employees, at the top of the page: "As of December 31, 2025, LivaNova had approximately 3,300 employees worldwide, representing more than 80 nationalities and located in 34 countries" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LIVN/export.csv") into a cell.